Back to School: How biopharma can reboot drug development. Access exclusive analysis here
KOSN fell $2.47 (43%) to $3.31 on Monday after reporting that 340 mg/m2 of its
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury